{"id":130849,"date":"2026-07-08T14:51:22","date_gmt":"2026-07-08T20:51:22","guid":{"rendered":"https:\/\/trimrx.com\/blog\/?p=130849"},"modified":"2026-07-08T14:51:22","modified_gmt":"2026-07-08T20:51:22","slug":"what-is-efpeglenatide-a-once-weekly-glp-1-with-heart-protection-data","status":"publish","type":"post","link":"https:\/\/trimrx.com\/blog\/what-is-efpeglenatide-a-once-weekly-glp-1-with-heart-protection-data\/","title":{"rendered":"What Is Efpeglenatide? A Once-Weekly GLP-1 With Heart-Protection Data"},"content":{"rendered":"

Efpeglenatide is a once-weekly GLP-1 medication that stands out for one big reason: it’s backed by a major clinical trial showing it reduces the risk of heart attacks, strokes, and kidney problems in high-risk patients. Unlike most GLP-1 drugs, which are based on the human GLP-1 hormone, efpeglenatide is built from exendin (a related compound). It’s not FDA approved, though the South Korean company Hanmi is now pursuing approval for obesity. Here’s what makes its cardiovascular story notable and where things stand.<\/p>\n

The Cardiovascular Headline<\/h3>\n

GLP-1 drugs are increasingly valued not just for weight loss and blood sugar control but for protecting the heart. Efpeglenatide has some of the clearest evidence on this front. The AMPLITUDE-O trial, published in the New England Journal of Medicine<\/a> in 2021, studied efpeglenatide in more than 4,000 people with type 2 diabetes who also had cardiovascular or kidney disease, and found that the drug significantly reduced major cardiovascular events (heart attack, stroke, or cardiovascular death), which occurred in about 7% of the treated group versus roughly 9% on placebo. It also cut a composite measure of kidney decline by about a third.<\/p>\n

That result mattered beyond efpeglenatide itself. It confirmed that an exendin-based GLP-1 drug (a slightly different chemical class) could deliver the same kind of heart and kidney protection seen with human-GLP-1-based drugs.<\/p>\n

How It Works and How It’s Given<\/h3>\n

Efpeglenatide is a once-weekly subcutaneous injection. Like other GLP-1 drugs, it stimulates insulin release in a glucose-dependent way (lowering blood sugar with low hypoglycemia risk), slows stomach emptying, and reduces appetite, which supports weight loss. In obesity studies it has produced meaningful weight reduction, and a Korean phase 3 trial in adults with obesity reported about 9.75% average weight loss at 40 weeks, with fewer gastrointestinal side effects than some patients experience on other GLP-1 drugs.<\/p>\n

Quick Facts<\/h3>\n
\n\n\n\n\n\n\n\n\n\n\n
Feature<\/th>\nDetail<\/th>\n<\/tr>\n<\/thead>\n
Current developer<\/td>\nHanmi Pharmaceutical<\/td>\n<\/tr>\n
Type<\/td>\nExendin-based GLP-1 receptor agonist<\/td>\n<\/tr>\n
Administration<\/td>\nOnce-weekly injection<\/td>\n<\/tr>\n
Status<\/td>\nInvestigational (not FDA approved)<\/td>\n<\/tr>\n
Signature data<\/td>\nReduced cardiovascular and kidney events (AMPLITUDE-O)<\/td>\n<\/tr>\n
Obesity data<\/td>\nAbout 9.75% weight loss at 40 weeks (phase 3, Korea)<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<\/div>\n

A Winding Development Path<\/h3>\n

Efpeglenatide’s history is a bit of a journey. It was originally developed by Hanmi, licensed to the French company Sanofi (which ran the large global trials including AMPLITUDE-O), then returned to Hanmi. Hanmi is now advancing it as a homegrown Korean obesity drug, having filed for approval in South Korea in late 2025 and targeting a launch there in the second half of 2026. Consider a hypothetical patient with both obesity and heart disease weighing their options. A GLP-1 with proven cardiovascular benefit would be attractive, which is the profile efpeglenatide is positioning around, though its availability depends heavily on where you live.<\/p>\n

What This Means for You Right Now<\/h3>\n

For patients in the United States, efpeglenatide is not available, and TrimRx does not offer it. TrimRx provides medications you can access today, including compounded semaglutide and compounded tirzepatide plus brand options like Ozempic, Wegovy, Mounjaro, and Zepbound (some of which also carry cardiovascular benefit data of their own). If you’re focused on weight loss now, those available options are where to look.<\/p>\n

Efpeglenatide is a notable drug for its heart and kidney data, but its path to patients (especially outside Korea) remains uncertain.<\/p>\n

Frequently Asked Questions<\/h3>\n

Is efpeglenatide FDA approved?<\/h4>\n

No. Efpeglenatide is not FDA approved and is not available in the United States. Hanmi has filed for approval in South Korea and is targeting a launch there in 2026, but that would be a Korean approval, not a US one.<\/p>\n

What makes efpeglenatide different from other GLP-1 drugs?<\/h4>\n

Two things: it’s built from exendin rather than the human GLP-1 hormone, and it has strong cardiovascular outcome data from the AMPLITUDE-O trial, showing reduced heart and kidney events in high-risk diabetes patients. Several other GLP-1 drugs also have cardiovascular benefit data.<\/p>\n

Can TrimRx prescribe efpeglenatide?<\/h4>\n

No. TrimRx offers medications that are currently available, such as compounded semaglutide and tirzepatide and brand GLP-1 options. Efpeglenatide is not available in the US and is not among TrimRx’s offerings.<\/p>\n

To focus on what you can actually start with, you can explore the options available to you now<\/a> with a licensed provider.<\/p>\n

This information is for educational purposes and is not medical advice. Efpeglenatide is investigational in the US and not FDA approved; details and timelines may change. Consult a healthcare provider before starting any medication. Individual results may vary.<\/em><\/p>\n","protected":false},"excerpt":{"rendered":"

Efpeglenatide is a once-weekly GLP-1 medication that stands out for one big reason: it’s backed by a major clinical trial showing it reduces the…<\/p>\n","protected":false},"author":7,"featured_media":93550,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"inline_featured_image":false,"_yoast_wpseo_title":"","_yoast_wpseo_metadesc":"","_yoast_wpseo_focuskw":"","footnotes":"","_flyrank_wpseo_metadesc":""},"categories":[6],"tags":[],"class_list":["post-130849","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-glp-1"],"_links":{"self":[{"href":"https:\/\/trimrx.com\/blog\/wp-json\/wp\/v2\/posts\/130849","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/trimrx.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/trimrx.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/trimrx.com\/blog\/wp-json\/wp\/v2\/users\/7"}],"replies":[{"embeddable":true,"href":"https:\/\/trimrx.com\/blog\/wp-json\/wp\/v2\/comments?post=130849"}],"version-history":[{"count":1,"href":"https:\/\/trimrx.com\/blog\/wp-json\/wp\/v2\/posts\/130849\/revisions"}],"predecessor-version":[{"id":130850,"href":"https:\/\/trimrx.com\/blog\/wp-json\/wp\/v2\/posts\/130849\/revisions\/130850"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/trimrx.com\/blog\/wp-json\/wp\/v2\/media\/93550"}],"wp:attachment":[{"href":"https:\/\/trimrx.com\/blog\/wp-json\/wp\/v2\/media?parent=130849"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/trimrx.com\/blog\/wp-json\/wp\/v2\/categories?post=130849"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/trimrx.com\/blog\/wp-json\/wp\/v2\/tags?post=130849"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}